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INTRODUCTION
Formulations administered via the oral routes of drug administration represent 50-60% of the total dosage forms. The oral route of administration is considered as the most widely accepted route because of its convenience, ease of administration, pain avoidance and patient compliance. Difficulty in swallowing (Dysphagia) is a common problem of all age groups, especially elderly and pediatrics, because of physiological changes associated with these groups of patients. Many pediatric and geriatric patients are unwilling to take solid preparations due to a fear of choking. Also the swallowing of oral dosage forms needs water which is sometimes not available 1 . For these reasons, tablets that can rapidly dissolve or disintegrate in the oral cavity have attracted a great deal of attention 2&3 . These tablets are called fast dissolving tablets, orally disintegrating tablets (ODTs) or mouthdissolving tablets. Fast dissolving tablets are those when put on tongue disintegrate instantaneously releasing the drug which dissolve or disperses in the saliva 4 . Orally disintegrating tablets are considered as solid oral preparations that disintegrate rapidly in the oral cavity with an in-vitro disintegration time less than 30 seconds, when based on the United States Pharmacopeia disintegration test method and FDA guidance 5 . The basic approach in development of fast disintegrating tablets (FDT) is the use of superdisintegrants like cross linked carboxymethyl cellulose (croscarmellose), sodium starch glycolate (primogel, explotab), polyvinylpyrollidone (polyplasdone) etc, which provide instantaneous disintegration of tablet after putting on the tongue. The bioavailability of some drugs may be increased due to absorption of part of drug in the oral cavity and also due to pregastric absorption of saliva containing dispersed drugs that pass down into the stomach. Moreover, the amount of drug that is subjected to first pass metabolism is reduced as compared to conventional tablet 6 . Meclizine HCl (MZ HCl) is a firstgeneration antihistamine of the piperazine class.
Meclizine is structurally and pharmacologically similar to buclizine, cyclizine, and hydroxyzine, but has a shorter half-life of 6 hrs compared to cyclizine and hydroxyzine with about 20 hrs. It is used as an antivertigo/antiemetic agent, specifically in the prevention and treatment of nausea, vomiting, and dizziness associated with motion sickness. It possesses anticholinergic, central nervous system depressant, and local anesthetic effects. Its antiemetic and antivertigo effects are not fully understood, but its central anticholinergic properties are partially responsible. The drug depresses labyrinth excitability and vestibular stimulation, and it may affect the medullary chemoreceptor trigger zone 7 . The aim of the present work was to prepare MZ HCl fast dissolving tablets by direct compression method and to study the effect of the type and concentration of different superdisintegrants on the physical properties of the prepared tablets. The direct compression technique was selected rather than wet granulation because the porous nature of the prepared tablets by direct compression gives faster disintegration. 
MATERIALS AND METHODS

Meclizine
Methodology
Differential scanning calorimetry (DSC)
The thermal behavior of MZ HCl alone as well as its physical mixtures with tablet excipients was studied using DSC technique. The sample (3-5 mg) was hermetically sealed in aluminum pans and heated at a constant rate of 10°C/min, over a temperature range of 25°C to 250°C. Thermograms of the samples were obtained using differential scanning calorimetry (DSC-60, Shimadzu, Japan). Thermal analysis data were recorded using a TA 50I PC system with Shimadzu software programs. Indium standard was used to calibrate the DSC temperature and enthalpy scale. N 2 was used as purging gas at rate of 30 ml/min.
Preparation of MZ HCl tablets by direct compression method
The corresponding amounts of MZ, avicel pH 101 and superdisintegrant (Table 1) were accurately weighed and mixed using Turbula mixer (Erweka, S2Y, Heusenstamm, Germany) for five minutes. Thereafter, the corresponding amount of mannitol was accurately weighed, added to the mixture and mixed for 10 min. Finally the amount of magnesium stearate was mixed with the powder in the turbula mixer for further 2 min. The powder was compressed into tablets weighing 200 mg using Korsh single punch machine with 9 mm shallow concave punches (Erweka, EKO, Germany).
Evaluation of the prepared tablets Weight variation
Twenty tablets from each batch were individually weighed (Analytical balance, Shimadzu, EB-3200D, Tyoto, Japan), the average weight and standard deviation were calculated.
Thickness
Ten pre-weighed tablets were tested for thickness using a micrometer (Starrett, Athol MA, USA), the average thickness and standard deviation were calculated.
Hardness
Tablet hardness was determined with the Hardness Tester (Pharma test GmbH, Hainburg, Germany) for 10 tablets (with known weight and thickness) of each batch; the average hardness and standard deviation were reported.
Friability
Tablet friability was determined according to USP30-NF25. In brief, twenty tablets were weighed (W 1 ) and placed into the friabilator (Erweka, TA3R, Heusenstamm, Germany), which was rotated at 25 rpm for 4 min. The tablets then reweighed after removal of fines (W 2 ), and the loss % was calculated by: 100 × (W 1 − W 2 )/W 1 .
MZ HCl content
A meclizine HCl orally disintegrating tablet weighing 200 mg and equivalent to 25 mg meclizine was accurately weighed, finely powdered, and transferred into a volumetric flask. About 60 ml of 0.1 N HCl was added, sonicated for 10 min, then shaken by mechanical means for 30 min and completed to 100 ml with the same solvent and then sonication and filtration was performed. The drug content was determined spectrophotometrically at 232 nm 8 . Test was performed on placebo, fresh, and conditioned meclizine ODT and repeated in triplicates.
In-vitro disintegration
In-vitro disintegration test was assessed according to the USP30-NF25 requirements. One dosage unit was introduced into each of the six tubes of the basket (Electrolab, ED-21, Mumbai, India). The apparatus was operated, using phosphate buffer (pH 6.8) as the immersion fluid, maintained at 37°C ± 2°C. Time for complete disintegration of each tablet was determined and standard deviation of 6 tablets was calculated.
In-vitro dissolution studies
The release measurements were performed using USP dissolution apparatus 2, paddle method, (Caleva Ltd., Model 85T), at 100 rpm using a continuous automated monitoring system. This system consists of an IBM computer PK8620 series and PU 8605/60 dissolution test software, Philips VIS/UV/NIR single beam eight cell spectrophotometer Model PU 8620, Epson FX 850 printer, and Watson-Marlow peristaltic pump using in each flask a 500 mL 0.1N HCl, pH 1.2. The temperature was maintained at 37±0.5°C. At predetermined times intervals (5, 10, 15, 20 and 30 min), absorbances were recorded automatically at 232 nm and the percentage of drug released was determined as a function of time. Test was done on MZ HCl containing tablets in triplicates.
In-vivo disintegration and palatability studies
A taste panel consisting of 12 healthy male volunteers (30-55 years old) have tried a selected formula (F3). The tested tablet was kept in mouth until disintegration, then disgorged. The taste, its extent, after taste and other effects such as numbness if any were evaluated as shown in table 2. Figures 1a and b show the DSC thermograms of MZ HCl alone, excipients alone (mannitol, SSG, CPV and CCS) and the physical mixture of MZ HCl and excipent (1:1). It is clear that MZ HCl exhibits an endothermic peak at about 210ºC due to melting of the drug. This endothermic peak has been seen again in the physical mixture of MZ HCl with excipients with lower intensity due to the dilution effect. However, in case of physical mixture of MZ HCl and mannitol, the endothermic peak of MZ HCl disappeared. This might be due to the solubility of MZ HCl in the molten mannitol (m.p. 170ºC). IR study was conducted to detect any chemical interaction of MZ HCl with mannitol, which shown in figure 2. It is clear from this figure that there is no chemical interaction between MZ HCl and mannitol as the characteristic peak of MZ HCl (1392 cm -1 ) appeared again in the physical mixture with no shift.
RESULTS AND DISCUSSION
DSC study
Tablet evaluation
The orally disintegrating tablets containing 25 mg MZ HCl was successfully prepared using direct compression method. The manufactured ODTs were evaluated for their weight uniformity, thickness; hardness, friability, MZ HCl content as well as disintegration time, and the obtained data are summarized in table 3. The weight of the tablets in all formulations was found to be in the range of 0.199 g -0.202 g and the average tablet thickness was found to be 3.5±0.1 mm. Moreover, the tablets exhibited acceptable friability that is less than 1% in all ODTs formulations.
Tablet disintegration
The effect of different disintegrants on the disintegration time of ODTs containing 25 mg MZ HCl is displayed in table 3 and figure 3. It is clearly evident from the data that the used superdisintegrants cause a pronounced decrease in the disintegration time of the prepared ODTs, especially CCS and CPV. Tablets formulated without superdisintegrants exhibited disintegration time of about 36 seconds. In case of using CCS and CPV as superdisintegrants, increasing the superdisintegrant concentration from 2% to 5% resulted in enhancing tablets disintegration by decreasing disintegration time. In addition, increasing the concentration of CCS and CPV from 5% to 10% in the tablets did not show any significant increase in the disintegration rate. Also, increasing the concentration of SSG from 2% to 5% resulted in a pronounced reduction of disintegration time from 33 seconds to 25 seconds, while increasing the concentration of the superdisintegrant from 5% to 10% did not show any significant action. It can be concluded that the optimum concentration of the superdisintegrant is 5%, which gave rapid disintegration of MZ HCl tablets. These results are in accordance with Shankarrao et al. 9 , who showed that a concentration of 5% CCS gave minimum disintegration time and the maximum dissolution rate. Also, Ferrero et al. 10 , studied the disintegration efficiency of croscarmellose sodium and reported that at high concentrations (> 8%), the disintegration time was found to increase. Moreover, Jagdale et al.
11
, mentioned that croscarmellose sodium gave a low disintegration time initially and then a sudden rise occurs from 4 to 6%. They interpreted these results on the basis of that the disintegration action of croscarmellose sodium at low concentrations in tablet is due to its fibrous nature, which allows wicking of water into tablet matrices. At lower concentrations the fibrous nature is more pronounced and smoothens gradually with time. At high concentrations, there is a probability that wicking and swelling occurs simultaneously thus, smoothening the particles and the width of the pore decreases.
It could be concluded that tablet formulations containing 5% CCS and 5% CPV (F3 and F9, respectively) could be considered as optimum due to their shortest disintegration time.
In-vitro dissolution
The in-vitro dissolution profiles of MZ HCl from the prepared oral disintegrating tablets are displayed in figures 4-6. The drug exhibited only 5% dissolution from the tablet formula containing no superdisintegrant after the first 5 min, and completed dissolution after 15 min. This observation is complying with the higher disintegration time obtained with such formula (36 seconds). However, the presence of superdisintegrants in the tablet formulations caused an enhanced initial dissolution rate of MZ HCl, especially at 5% superdisintegrant level. For example, 95.67, 93.67, 97.33% of the loaded MZ HCl were dissolved from ODTs containing 5% concentration of CCS, CPV and SSG, respectively. The dissolution of MZ HCl from ODTs formulations F3 and F6 (containing 5% of each CCS and SSG, respectively) was studied in different dissolution media, viz., pH 1.2 and pH 6.8 and the results are displayed in figure 7 . The drug exhibited very slow dissolution rates from these formulas in the higher pH value (not more than 17% were released after 30 min), while complete drug dissolution from both formulas was observed after 15 min at low pH (pH 1.2). This phenomenon is due to the lower solubility of MZ HCl in the higher pH values 7 . This might be advantageous during the formulation of MZ HCl ODTs, since the manufactured ODTs formulations containing the drug exhibited rapid disintegration in this higher pH values (pH 6.8), which simulates saliva fluid, while the drug dissolves slowly, which may result in masking its undesirable taste. Tables 4&5 show the results of palatability test. Taste evaluation results show that the response of half of the volunteers was acceptable while the other half showed good response. Only two volunteers out of twelve complained a mild bitter after taste. Mouth feel results show that the response of ten of the volunteers was acceptable while the other two showed good response with no complain of numbness. These results indicate an acceptable palatability of the formulated tablets. The mean in-vivo disintegration time for the 12 volunteers was about 10 seconds which is in accordance with the in-vitro disintegration time for F3. 
Evaluation of palatability
